ABL 002Alternative Names: ABL002
Latest Information Update: 11 Mar 2017
At a glance
- Originator ABL Bio
- Class Antineoplastics; Bispecific antibodies
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Head and neck cancer
Most Recent Events
- 09 Mar 2017 Early research in Head and neck cancer in South Korea (Parenteral)